Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 494,296
  • Shares Outstanding, K 56,298
  • Annual Sales, $ 23,610 K
  • Annual Income, $ -105,510 K
  • EBIT $ -24 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.01
  • Price/Sales 20.77
  • Price/Cash Flow N/A
  • Price/Book 3.67

Options Overview Details

View History
  • Implied Volatility 114.95% (-43.64%)
  • Historical Volatility 59.73%
  • IV Percentile 52%
  • IV Rank 25.30%
  • IV High 304.21% on 11/14/25
  • IV Low 50.87% on 05/22/25
  • Expected Move (DTE 10) 0.81 (9.25%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 105
  • Volume Avg (30-Day) 906
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 61,533
  • Open Int (30-Day) 63,378
  • Expected Range 7.92 to 9.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.05
  • Number of Estimates 3
  • High Estimate 0.07
  • Low Estimate 0.02
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +107.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.01 +9.04%
on 11/21/25
9.95 -12.21%
on 11/18/25
-0.08 (-0.85%)
since 11/07/25
3-Month
7.16 +22.00%
on 09/17/25
12.03 -27.39%
on 10/16/25
+0.52 (+6.39%)
since 09/09/25
52-Week
6.19 +41.11%
on 04/09/25
13.16 -33.62%
on 07/15/25
-0.13 (-1.41%)
since 12/09/24

Most Recent Stories

More News
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.70 (-0.91%)
Zevra Therapeutics, Inc. Announces CFO Transition

CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.70 (-0.91%)
Zevra Therapeutics: Q3 Earnings Snapshot

Zevra Therapeutics: Q3 Earnings Snapshot

ZVRA : 8.70 (-0.91%)
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million , driven by MIPLYFFA ® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5,...

ZVRA : 8.70 (-0.91%)
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.70 (-0.91%)
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.70 (-0.91%)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.70 (-0.91%)
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium...

MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC...

ZVRA : 8.70 (-0.91%)
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award...

ZVRA : 8.70 (-0.91%)
Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.70 (-0.91%)

Business Summary

Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. Zevra Therapeutics, formerly known as KemPharm Inc., is based in CELEBRATION, Fla.

See More

Key Turning Points

3rd Resistance Point 9.26
2nd Resistance Point 9.15
1st Resistance Point 8.96
Last Price 8.70
1st Support Level 8.66
2nd Support Level 8.55
3rd Support Level 8.36

See More

52-Week High 13.16
Fibonacci 61.8% 10.50
Fibonacci 50% 9.68
Fibonacci 38.2% 8.85
Last Price 8.70
52-Week Low 6.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar